Vulvovaginal Candidiasis Treatment Market Insights, Research and Growth Factor till 2032

Posted by Ganesh Shinde on January 20th, 2023

The global vulvovaginal candidiasis treatment market is currently valued at US$ 1035 million in 2023, with a CAGR of 4.5% expected. Because of technological advancements in the healthcare sector, the market is expected to reach US07 million by 2033.

Individuals' VVC prevalence has increased due to an increase in diabetes cases and repeated antibiotic use. The market is expected to expand as R&D initiatives for precise diagnosis increase.

The rapid growth rate can be attributed to the increasing disease burden of VVC as well as higher testing rates. Positive changes such as government healthcare benefits, increased consumer awareness, and willingness to use medical treatments are also expected to drive the growth of the vulvovaginal candidiasis treatment market.

Rapid increase in the global disease burden, coupled with escalating demand for better treatment options and increasing number of hospital-acquired infections, is also propelling the demand for bacterial vulvovaginal candidiasis treatment. 

Furthermore, expanding healthcare infrastructure in developing economies, availability of pharmaceutical drugs, and robust technological advancements in the biopharmaceutical industries are all contributing to significant opportunities for vulvovaginal candidiasis treatment over the forecasted period.

Competitive Landscape

Astellas Pharma Inc., Mycovia Pharmaceuticals, Inc., Basilea Pharmaceutica Ltd., Scynexis, Inc., Grupo Ferrer Internacional S.A., Pfizer, Inc.,Cadila Pharmaceuticals,Bayer AG., Bristol-Myers Squibb Company are some of the key companies in the vulvovaginal candidiasis treatment market.

Get More Insights@ https://www.futuremarketinsights.com/reports/vulvovaginal-candidiasis-treatment-market

Key Segments Covered in the Vulvovaginal Candidiasis Treatment Market Industry Survey

Vulvovaginal Candidiasis Treatment Market by Drug Class:

• Clotrimazole
• Nystatin
• Fluconazole
• Ketoconazole
• Terbinafine
• Terconazole
• Others

Vulvovaginal Candidiasis Treatment Market by Route of Administration:

• Oral Vulvovaginal Candidiasis Treatment
• Intravenous Vulvovaginal Candidiasis Treatment
• Topical Vulvovaginal Candidiasis Treatment

Vulvovaginal Candidiasis Treatment Market by Distribution Channel:

• Hospital Pharmacy for Vulvovaginal Candidiasis Treatment
• Retail Pharmacy for Vulvovaginal Candidiasis Treatment
• Online Pharmacy for Vulvovaginal Candidiasis Treatment